Cargando…
A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563497/ https://www.ncbi.nlm.nih.gov/pubmed/36229845 http://dx.doi.org/10.1186/s41232-022-00230-w |
_version_ | 1784808417512128512 |
---|---|
author | Farid, Mariam F. Abouelela, Yara S. Yasin, Noha A. E. Mousa, Mohamed R. Ibrahim, Marwa A. Prince, Abdelbary Rizk, Hamdy |
author_facet | Farid, Mariam F. Abouelela, Yara S. Yasin, Noha A. E. Mousa, Mohamed R. Ibrahim, Marwa A. Prince, Abdelbary Rizk, Hamdy |
author_sort | Farid, Mariam F. |
collection | PubMed |
description | BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study was conducted on 15 adult Persian cats that were divided into three groups: control negative, control positive (ethidium bromide (EB)-treated group), and PRP co-treated group (EB-treated group intrathecally injected with PRP on day 14 post-spinal cord injury). PRP was obtained by centrifuging blood on anticoagulant citrate dextrose and activating it with red and green laser diodes. The Basso–Beattie–Bresnahan (BBB) scores were used to assess the motor function recovery on days 1, 3, 7, 14, 20, and 28 following 14 days from EB injection. Moreover, magnetic resonance imaging (MRI) analysis, histopathological investigations, transmission electron microscopy (TEM) studies, and immunohistochemical analysis were conducted, and the gene expressions of nerve growth factors (NGFs), brain-derived neurotrophic factors (BDNF), and stromal cell-derived factors (SDF) were evaluated. RESULTS: Our results indicated that PRP had a significant ameliorative effect on the motor function of the hindlimbs as early as day 20 and so on. MRI revealed that the size and intensity of the lesion were significantly reduced in the PRP co-treated group. The histopathological and TEM investigations demonstrated that the PRP co-treated group had a significant improvement in the structure and organization of the white matter, as well as a high remyelination capacity. Furthermore, a significant increase in myelin basic protein and Olig2 immunoreactivity as well as a reduction in Bax and glial fibrillar acidic protein immune markers was observed. NGFs were found to be upregulated by gene expression. CONCLUSION: As a result, we concluded that the intrathecal injection of PRP was an effective, safe, and promising method for the treatment of MS. |
format | Online Article Text |
id | pubmed-9563497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95634972022-10-15 A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats Farid, Mariam F. Abouelela, Yara S. Yasin, Noha A. E. Mousa, Mohamed R. Ibrahim, Marwa A. Prince, Abdelbary Rizk, Hamdy Inflamm Regen Research Article BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study was conducted on 15 adult Persian cats that were divided into three groups: control negative, control positive (ethidium bromide (EB)-treated group), and PRP co-treated group (EB-treated group intrathecally injected with PRP on day 14 post-spinal cord injury). PRP was obtained by centrifuging blood on anticoagulant citrate dextrose and activating it with red and green laser diodes. The Basso–Beattie–Bresnahan (BBB) scores were used to assess the motor function recovery on days 1, 3, 7, 14, 20, and 28 following 14 days from EB injection. Moreover, magnetic resonance imaging (MRI) analysis, histopathological investigations, transmission electron microscopy (TEM) studies, and immunohistochemical analysis were conducted, and the gene expressions of nerve growth factors (NGFs), brain-derived neurotrophic factors (BDNF), and stromal cell-derived factors (SDF) were evaluated. RESULTS: Our results indicated that PRP had a significant ameliorative effect on the motor function of the hindlimbs as early as day 20 and so on. MRI revealed that the size and intensity of the lesion were significantly reduced in the PRP co-treated group. The histopathological and TEM investigations demonstrated that the PRP co-treated group had a significant improvement in the structure and organization of the white matter, as well as a high remyelination capacity. Furthermore, a significant increase in myelin basic protein and Olig2 immunoreactivity as well as a reduction in Bax and glial fibrillar acidic protein immune markers was observed. NGFs were found to be upregulated by gene expression. CONCLUSION: As a result, we concluded that the intrathecal injection of PRP was an effective, safe, and promising method for the treatment of MS. BioMed Central 2022-10-14 /pmc/articles/PMC9563497/ /pubmed/36229845 http://dx.doi.org/10.1186/s41232-022-00230-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Farid, Mariam F. Abouelela, Yara S. Yasin, Noha A. E. Mousa, Mohamed R. Ibrahim, Marwa A. Prince, Abdelbary Rizk, Hamdy A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title | A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title_full | A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title_fullStr | A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title_full_unstemmed | A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title_short | A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats |
title_sort | novel cell-free intrathecal approach with prp for the treatment of spinal cord multiple sclerosis in cats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563497/ https://www.ncbi.nlm.nih.gov/pubmed/36229845 http://dx.doi.org/10.1186/s41232-022-00230-w |
work_keys_str_mv | AT faridmariamf anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT abouelelayaras anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT yasinnohaae anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT mousamohamedr anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT ibrahimmarwaa anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT princeabdelbary anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT rizkhamdy anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT faridmariamf novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT abouelelayaras novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT yasinnohaae novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT mousamohamedr novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT ibrahimmarwaa novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT princeabdelbary novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats AT rizkhamdy novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats |